Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Levitra · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| Arm 1 | EXPERIMENTAL | - |
| Arm 2 | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Levitra (Vardenafil, BAY38-9456) | DRUG | 20mg to be taken 1 h prior to sexual intercourse |
| Placebo | DRUG | Matching placebo |
Inclusion Criteria: * Men \>/= 18 years of age, with 6 months or longer diagnosis of ED as defined by NIH Consensus statement, * History of unresponsiveness to sildenafil * Stable sexual relationship for \> 6 month. Exclusion Criteria: * Primary hypoactive sexual desire * History of myocardial in...
Levitra is used for the treatment of erectile dysfunction in men. It is a small molecule being developed by GSK plc (ticker: GSK) and is currently in Phase 3 clinical development. Two Phase 3 trials have been completed, studying its efficacy and safety in men with erectile dysfunction.
Levitra is being developed by GSK plc, which trades under the ticker GSK. The drug is currently in Phase 3 clinical development for erectile dysfunction. GSK has completed two Phase 3 trials evaluating Levitra in this indication.
Levitra is in Phase 3 clinical development for erectile dysfunction. Two Phase 3 trials have been completed, both of which were randomized, double-blind, and placebo-controlled. The drug is investigational and has not been approved by regulatory authorities based on the available data.
Levitra has been studied in two completed Phase 3 clinical trials. The first, NCT00658177, evaluated flexible-dose vardenafil in subjects with erectile dysfunction and enrolled 463 participants. The second, NCT00668005, evaluated vardenafil in subjects with erectile dysfunction and hypertension, enrolling 388 participants.
Levitra is the brand name for vardenafil, a small molecule used to treat erectile dysfunction. The clinical trials for Levitra, including NCT00658177 and NCT00668005, refer to vardenafil as the active substance. Both trials were Phase 3, randomized, double-blind, and placebo-controlled.